Long-term GERD management: The individualized approach

Drugs of Today

Volumn 42, Issue SUPPL. B, 2006, Pages 23-29

  Tytgat, Guido N J ^a,b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b NONE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; NIZATIDINE; OMEPRAZOLE; PANTOPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR;

CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESOPHAGUS DISEASE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; HUMAN; LONG TERM CARE; NONEROSIVE REFLUX DISEASE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REFLUX ESOPHAGITIS; RELAPSE; TREATMENT INDICATION;

EID: 33947282794     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (22)

1. Fletcher, J., Wirz, A., Young, J., Vallance, R., McColl, K.E. Unbuffered highly acidic gastric juice exists at the gastroesophageal junction after a meal. Gastroenterology 2001, 121(4): 775-83.
2. Talley, N. Dyspepsia: How to manage and how to treat? Aliment Pharmacol Ther 2002, 16(4): 95-104.
3. Bardhan, K.D. Intermittent and on-demand use of proton pump inhibitors in the management of symptomatic gastroesophageal reflux disease. Am J Gastroenterol 2003, 98 (Suppl): S40-8.
4. Hungin, A.P.S., Rubin, O'Flanagan, H. Factors influencing compliance in long-term proton pump inhibitor therapy in general practice. Br J Gen Pract 1999, 49: 463-4.
5. Kaspari, S., Kupcinskas, L., Heinze, H., Berghofer, P. Pantoprazole 20 mg on demand is effective in the long-term management of patients with mild gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2005, 17(9): 935-41.
6. Scholten, T., Dekkers, C.P.M., Schütze, K., Körner, T., Bohuschke, M., Gatz, G. On-demand therapy with pantoprazole 20 mg as effective long-term management of reflux disease in patients with mild GERD: The ORION trial. Digestion 2005, 72: 76-85.
7. Scholten, T., Pustlauk, U., Sander, P., Bohuschke, M., Gatz, G. Pilot study of on-demand therapy with pantoprazole 20 mg for long-term treatment in patients with mild gastro-esophageal reflux disease. Clin Drug Invest 2005, 25(10): 633-42.
8. Janssen, W., Meier, E., Gatz, G., Pfaffenberger, B. Effects of pantoprazole 20 mg in mild gastroesophageal reflux disease: Once-daily treatment in the acute phase, and comparison of on-demand versus continuous treatment in the long term. Curr Ther Res 2005, 66(4): 345-63.
9. Scholten, T., Bohuschke, M., Gatz, G. On-demand therapy with pantoprazole 20 mg leads to lower heartburn intensity than with esomeprazole 20 mg in patients with mild GERD. Gut 2005, 54 (Suppl VII): A109.
10. Sjöstedt, S., Befrits, R., Sylvan, A. et al. Daily treatment with esomeprazole is superior to that taken on-demand for maintenance of healed erosive oesophagitis. Aliment Pharmacol Ther 2005, 22(3): 183-91.
11. Shaker, R., Castell, D.O., Schoenfeld, P.S., Spechler, S.J. Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: The results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am J Gastroenterol 2003, 98(7): 1487-93.
12. Richter, J.E., Bochenek, W. Oral pantoprazole for erosive esophagitis: A placebo-controlled, randomized clinical trial. Pantoprazole US GERD Study Group. Am J Gastroenterol 2000, 95(11): 3071-80.
13. Scholten, T., Gatz, G., Hole, U. Once-daily pantoprazole 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD-related symptoms. Aliment Pharmacol Ther 2003, 18: 587-94.
14. Janz, M., Doerfler, H. Pantoprazole is superior to both omeprazoles and to nizatidine with regards to final relief from nighttime heartburn in patients with erosive GERD. Gut 2004, 53 (Suppl VI): A104.
15. Gillessen, A., Beil, W., Modlin, I.M., Gatz, G., Hole, U. 40 mg pantoprazole and 40 mg esomeprazole are equivalent in the healing of esophageal lesions and relief from gastroesophageal reflux disease-related symptoms. J Clin Gastroenterol 2004, 38: 332-40.
16. Körner, T., Schütze, K., van Leendert, R.J.M. et al. Comparable efficacy of pantoprazole and omeprazole in patients with moderate to severe reflux esophagitis. Results of a multinational study. Digestion 2003, 67: 6-13.
17. Castell, D.O., Kahrilas, P.J., Richter, J.E. et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002, 97(3): 575-83.
18. Malfertheiner, P., Lind, T., Willich, S. et al. Prognostic influence of Barrett's oesophagus and Helicobacter pylori infection on healing of erosive gastro-oesophageal reflux disease (GORD) and symptom resolution in non-erosive GORD: Report from the ProGORD study. Gut 2005, 54(6): 746-51.
19. Metz, D.C., Bochenek, W.J. for the Pantoprazole US GERD Study Group. Pantoprazole maintenance therapy prevents relapse of erosive oesophagitis. Aliment Pharmacol Ther 2003, 17: 155-64.
20. Richter, J.E., Fraga, P., Mack, M., Sabesin, S.M., Bochenek, W. for the Pantoprazole US GERD Study Group. Prevention of erosive oesophagitis relapse with pantoprazole. Aliment Pharmacol Ther 2004, 20: 567-75.
21. Goh, K., Wu, C., Benamouzig, R. et al. Pantoprazole 20 mg is as effective as esomeprazole 20 mg in maintaining complete remission for six months in patients with healed gastroesophageal reflux disease. Gut 2005, 54 (Suppl VII): A108.
22. Heinze, H., Preinfalk, J., Athmann, C., Bethke, T., Brunner, G. Clinical efficacy and safety of pantoprazole in severe acid-peptic disease during up to 10 years maintenance treatment. Gut 2003, 52 (Suppl VI): A63.